What Happened

Vertex Pharmaceuticals reported phase 3 data for ALYFTREK in children aged 2-5 with cystic fibrosis at the European Cystic Fibrosis Conference, with 92% achieving target sweat chloride levels. MannKind presented new pediatric safety and satisfaction data for Afrezza inhaled insulin at ADA 2026. Rhythm Pharmaceuticals shared 6-month interim phase 2 results for setmelanotide in Prader-Willi syndrome at ENDO 2026.

Who Is Affected

Pediatric pulmonologists managing cystic fibrosis patients aged 2-5 years now have Vertex's ALYFTREK data to consider. Endocrinologists treating pediatric diabetes patients have new inhaled insulin options from MannKind. Geneticists and endocrinologists treating Prader-Willi syndrome patients may consider Rhythm's setmelanotide based on BMI reduction data.

Market Impact

• Vertex expands addressable market for CFTR modulators into younger pediatric populations
• MannKind's Afrezza gains traction in adolescent diabetes management
• Rhythm advances first pharmacological option for Prader-Willi syndrome

What to Watch

Monitor Vertex's regulatory submissions for ALYFTREK in 2-5 year olds in H1 2026. Track peer-reviewed publication of MannKind's pediatric inhaled insulin data. Follow Rhythm's completion of phase 2 PWS trial and regulatory strategy.